ARBIDOL suspension is a special children's antiviral drug for etiotropic therapy and prevention of influenza and SARS in children from 2 years of age

ARBIDOL - "suspension" is a special children's * antiviral drug for etiotropic therapy and prevention of influenza and SARS in children from 2 years of age .

Molecule benefits

• a wide range of antiviral activity: specifically inhibits influenza A and B viruses, including highly pathogenic subtypes - “pig” A (H1N1) pdm9 and “bird” A (H5N1), as well as other viruses that cause ARVI (parainfluenza virus, adenovirus, rhinovirus, coronavirus , PC virus and others);
• the action is aimed directly at influenza viruses and SARS - the main cause of colds
• direct antiviral effect is recognized and studied at the international level: umifenovir is included in the list of antiviral drugs for the treatment of influenza by experts of the International Society for Influenza and other SARSs 1 ; also presented in the rubricator of the World Health Organization (WHO) in the list of drugs with direct antiviral effect 2 - according to the mechanism of action, it refers to inhibitors of fusion (fusion);
• direct antiviral effect does not depend on the immunological status of the body, the reactivity of the immune system, the rate of production of interferons, as well as on the number of repeated courses of use of the drug;
• early readiness for action - the achievement of maximum concentrations in the blood after 1 hour from the time of taking the drug 3 ;
• therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the frequency of development of complications and exacerbations of chronic bacterial diseases 4.9 ;
• helps to reduce the period of the disease with influenza and SARS by up to 3 days, as well as reduce the risk of complications 4 :
  • pneumonia - by 96%;
  • sinusitis - by 92%;
  • bronchitis - by 84%;
  • otitis - by 95%;
• up to 4 times reduces the likelihood of developing complications of influenza and acute respiratory viral infections in frequently ill children and children with chronic diseases 5 ;
• many years of application experience, a favorable safety profile and comprehensive knowledge demonstrated in both numerous clinical studies 5 and observation programs 4.6
• representation in clinical guidelines for providing medical care for children with influenza 7 ;
• preventive use during the epidemic season, as well as in contact with a sick flu or other acute respiratory viral infections, reduces the risk of infection; in particular, when taken prophylactically during the period of the flu epidemic, it reduces the risk of infection of the child by up to 4 times 8

Advantages of powder release form for suspension preparation

• each bottle is equipped with a two-component polyethylene cap with a first opening control, which provides protection against independent use of the drug by children;
• the presence of dimensional risks around the circumference of the bottle clearly indicates the desired volume of liquid needed to prepare the suspension;
• the prepared suspension has a sweetish taste and a pleasant fruity cherry-banana flavor, which greatly facilitates the process of taking the drug by children;
• liquid dosage form provides babies with ease of swallowing;
• convenience and accuracy of dosing - the packaging of the drug is equipped with a convenient measuring spoon;
• storage and the possibility of using the prepared suspension - up to 10 days in a refrigerator.

Indications for use

• prevention and treatment of acute respiratory viral infections and influenza A and B in children from 2 years old and adults;
• complex therapy of acute intestinal infections of rotavirus etiology in children from 2 years.